Pelago Bioscience is a CRO providing in situ target engagement studies to accelerate preclinical and clinical drug discovery and development. Our patented Cellular Thermal Shift Assay (CETSA®), unlike other solutions on the market today, allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. The examples of CETSA® utility range from target identification and validation studies, MoA studies, lead generation, and lead optimization efforts, and drug candidate profiling to translational science and rational biomarker discovery. This makes CETSA® a keystone of decision-making throughout the drug discovery pipeline. Any time you need it.